Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Wednesday 17 October, 2018

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 4029E
GlaxoSmithKline PLC
17 October 2018
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

208

£14.516

226

£14.516

792

£14.516

207

£14.516

226

d)

Aggregated information

Aggregated volume Price

 

 

 

 

1659

£14.516

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

141

£14.516

117

£14.516

167

£14.516

117

d)

Aggregated information

Aggregated volume Price

 

 

 

 

543

£14.516

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

274

£14.516

205

£14.516

560

£14.516

274

£14.516

205

d)

Aggregated information

Aggregated volume Price

 

 

 

 

1518

£14.516

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

101

£14.516

74

£14.516

88

£14.516

101

£14.516

74

d)

Aggregated information

Aggregated volume Price

 

 

 

 

438

£14.516

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$38.47

84

$38.47

82

d)

Aggregated information

Aggregated volume Price

 

 

 

 

166

$38.47

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

159

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

129

£14.516

93

£14.516

162

£14.516

93

£14.516

129

d)

Aggregated information

Aggregated volume Price

 

 

 

 

606

£14.516

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Terrell

b)

Position/status

Chief Digital & Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$38.47

28

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

189

£14.516

141

£14.516

177

£14.516

189

£14.516

141

d)

Aggregated information

Aggregated volume Price

 

 

 

 

837

£14.516

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

 

 

 

 

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.516

115

£14.516

88

£14.516

110

d)

Aggregated information

Aggregated volume Price

 

 

 

 

313

£14.516

 

 

 

e)

Date of the transaction

2018-10-12

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHQDLFFVBFEFBX

a d v e r t i s e m e n t